Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03881098 · ClinicalTrials.gov registry record · NA
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
A NA study of Lung Cancer, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 2
- Study locations
NCT03881098: Recruiting NA study of Lung Cancer, sponsored by University of Colorado, Denver.
NCT03881098 is a NA study of Lung Cancer that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 240 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03881098, a NA study of Lung Cancer, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 2
- Study locations
Study Summary
This protocol pertains specifically to the prospective lung squamous cell carcinoma pre-malignant lesion (PML) cohort that will form a primary study group for the Lung Pre-Cancer Atlas.
Primary Outcome
Prospective data collection of histologic specimens for the purposes of reducing lung cancer mortalities.
Conditions Studied
Interventions
- PROCEDURE Venipuncture
- PROCEDURE Bronchoscopies
- PROCEDURE Sputum Sample
Study Locations (2)
Colorado
- Rocky Mountain Regional VAMC - Aurora
- UCHealth - Metro - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2019-12-06 |
| Est. Completion | 2028-01 |
| Phase | NA |
What NCT03881098 shows while recruiting
NCT03881098 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Venipuncture is the first listed.
NCT03881098 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03881098 about?
NCT03881098 is a clinical study titled "The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy". This protocol pertains specifically to the prospective lung squamous cell carcinoma pre-malignant lesion (PML) cohort that will form a primary study group for the Lung Pre-Cancer Atlas.
What is the current status of trial NCT03881098?
This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2019-12-06. Estimated completion is 2028-01.
What conditions does trial NCT03881098 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT03881098?
The interventions under investigation include: Venipuncture (PROCEDURE), Bronchoscopies (PROCEDURE), Sputum Sample (PROCEDURE).
Who is sponsoring clinical trial NCT03881098?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03881098 being conducted?
This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03881098's enrollment target sits among peer trials
240 117th of 409 higher than 292 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI